Hier finden Sie aktuelle Informationen von Mitgliedern des DNEbM
zum Thema Interessenkonflikte.

Weitere Informationen zum Thema Interessenkonflikte
erhalten Sie auch auf unserer Webseite

28. Juni 2010

Testimony Encouraging Greater FDA Transparency

Testimony of Peter Lurie, M.D., M.P.H., and Hillary Peabody, M.P.H., Health Research Group at Public Citizen Before the FDA Transparency Task Force 24 June 2010

Interessanter Beitrag der bekannten US-Verbraucherschutzgruppe zur FDA Anhörung zu Transparenz.

Volltext: http://www.citizen.org/Page.aspx?pid=573

24. Juni 2010

22. Juni 2010

From Evidence-based Medicine to Marketing-based Medicine: Evidence from Internal Industry Documents

von Glen I. Spielmans & Peter I. Parry
Bioethical Inquiry
DOI 10.1007/s11673-010-9208-8
Received: 2 October 2009 / Accepted: 15 December 2009

Download zum Artikel: http://www.springerlink.com/content/b674622731k4850q/fulltext.pdf

Abstract: While much excitement has been generated surrounding evidence-based medicine, internal documents from the pharmaceutical industry suggest that the
publicly available evidence base may not accurately represent the underlying data regarding its products. The industry and its associated medical communication firms state that publications in the medical literature primarily serve marketing interests. Suppression and spinning of negative data and ghostwriting have emerged as tools to help manage medical journal publications to best suit product sales, while disease mongering and market segmentation of physicians are also used to efficiently maximize profits. We propose that while evidence-based medicine is a noble ideal, marketing-based medicine is the current reality.

6. Juni 2010

Archiv interner Dokumente der pharmazeutischen Industrie

University of California, San Francisco: Drug Industry Document Archive
The Drug Industry Document Archive (DIDA) contains thousands of documents and resources about pharmaceutical industry clinical trials, publication of study results, pricing, marketing, relations with physicians and involvement in continuing medical education.

Most of these previously secret internal documents were made public as a result of lawsuits against a number of pharmaceutical companies including: Merck & Co., Parke-Davis, Warner-Lambert, Wyeth, and Pfizer. For further information on documents connected to these lawsuits, please consult The Documents.

Eine Befragung niedergelassener Fachärzte zum Umgang mit Pharmavertretern

Studie von Klaus Lieb und Simone Brandtönies im Deutschen Ärzteblatt vom 4.6.2010.
Dazu im Forum Gesundheitspolitik: "Ärzte und Pharmavertreter - eine verhängnisvolle Affäre"